GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » ROE % Adjusted to Book Value

Acerus Pharmaceuticals (TSX:ASP) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2022)


View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals ROE % Adjusted to Book Value?

Acerus Pharmaceuticals's ROE % for the quarter that ended in Sep. 2022 was 0.00%. Acerus Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2022 was N/A. Acerus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2022 was N/A.


Acerus Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Acerus Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals ROE % Adjusted to Book Value Chart

Acerus Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.35 - - - -

Acerus Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acerus Pharmaceuticals's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's ROE % Adjusted to Book Value falls into.



Acerus Pharmaceuticals ROE % Adjusted to Book Value Calculation

Acerus Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2021 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Acerus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acerus Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Executives
Samuel Herschkowitz Director
Edward Joseph Gudaitis Director, Senior Officer
Robert Martin Motz Senior Officer
Borys Chabursky Director
John Mark Lievonen Director
Norma Beauchamp Director
Stephen Robert Gregory Director

Acerus Pharmaceuticals Headlines